FDA approves Perrigo overactive bladder drug

Drug maker challenges patent on testosterone treatment

ALLEGAN, Mich. — The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said Wednesday.

Perrigo announced the approval of trospium chloride extended-release capsules in the 60 mg strength, a once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug is a generic version of Allergan's Sanctura XR, which has annual sales of $54 million, according to Symphony Health Solutions.

Perrigo also said it would challenge Eli Lilly's patent for the topical testosterone treatment Axiron by filing for approval of a generic version with the Food and Drug Administration, prompting Lilly and partnering company Acrux to file a lawsuit in the U.S. District Court for the Southern District of Indiana last week. According to Symphony Health Solutions, Axiron has annual sales of about $229 million.

Are you a pharmacy technician working in the retail industry? Find our group on Facebook for more stories like this and join the conversation.

Login or Register to post a comment.